Highest-materiality recent filing
Ludwig Enterprises closes $200K convertible note and warrant placement with Alumni Capital LP
Issued $250K convertible promissory note to Alumni Capital LP; maturity May 4, 2026; net proceeds $200K after original issue discount.
Ludwig Enterprises appoints Jose Antonio Reyes as Interim CEO effective October 1, 2025
Jose Antonio Reyes, who served as CEO from Aug 2024 to Apr 2025, returns as Interim CEO.
Ludwig Enterprises appoints Corain McGinn as Independent Director
Corain McGinn appointed as Independent Director effective September 5, 2025.
CEO Charles T. Todd Jr. resigns effective August 23, 2025; no replacement named yet
Charles T. Todd Jr. resigned as CEO of Ludwig Enterprises, effective August 23, 2025.
Ludwig Enterprises appoints Garth Lees-Rolfe as independent director
Garth Lees-Rolfe appointed independent director effective June 23, 2025.
Director Marvin S. Hausman resigns from board, remains Chief Scientific Officer
Dr. Marvin S. Hausman resigned from the Board of Directors on June 5, 2025.
Ludwig Enterprises publishes ASCO abstract on non-invasive breast cancer mRNA test
Abstract details mRNA signal from buccal cells combined with machine learning for breast cancer screening.
On June 23, 2025, the Board appointed a new independent director, Garth Lees-Rolfe, to hold office until the earlier of the expiration of the term of office, a successor is duly elected and qualified, or the earlier of her death, resignation, disqualification, or removal.
On June 5, 2025, the Board of Directors (the “Board”) of Ludwig Enterprises, Inc. (the “Company”) received a letter of resignation from Dr. Marvin S. Hausman from his position on the Board, Dr. Hausman will remain in his position as Chief Scientific Officer of the Company.
Max materiality 0.60 · Median 0.45 · Most common event leadership